τ成像在非典型帕金森症:初步证据[11 c] PBB3宠物在PSP的主题(S5.001)

文摘

目的:研究选择性区域绑定τ病理学体内,与c [11] PBB3 (c [11] methylamino pyridin-3-yl buta-1, 3-dienyl苯并[d] thiazol-6-ol)在PSP(进行性核上的麻痹症)患者,并评估与临床严重程度的相关性。背景:帕金森疾病的鉴别诊断可以挑战由于其临床的重叠。体内成像τ病理学与宠物是新兴作为更精确的诊断,临床生物标志物和未来的评估疾病修饰治疗。方法:动态PET扫描获得了喷丸后的70分钟(11 c) PBB3(平均剂量518.97兆贝可)在三个主题和8的同龄健康对照组。我们选择c [11] PBB3作为示踪剂由于其较高的特定活动,结合特异性高,血脑屏障通透性好,反应性与non-Alzheimer-typeτ病态和良好的示踪动力学属性。可能PSP-Parkinsonism诊断的对象包括三个7,10和12年的疾病症状出现以来的持续时间。使用多重线性参考组织模型结果进行了分析。结果:在健康对照组,没有区域选择性吸收。PSP的主题,保持最高的c [11] PBB3观察核,丘脑和黑质。这是符合区域负责临床症状,与先前的病理和τ积累的证据。 Longer disease duration and more advanced clinical severity were generally associated with higher tracer retention. Conclusions: All PSP-Parkinsonism phenotype patients showed increased retention of the tracer in the basal ganglia, as clinically expected, and giving in vivo evidence for tau pathology. Tau imaging is a promising tool for the assessment of diagnosis, prognosis, progression, and future monitoring of therapy in PSP and related conditions.

披露:佩雷斯博士索里亚诺没有披露。博士竞技场没有披露。Smith-Forrester博士没有披露。然而博士没有披露。Shahinfard博士没有披露。苗族没有披露博士。谢弗博士没有披露。Shinotoh博士没有披露。Higuchi博士没有披露。Sossi博士没有披露。 Dr. Stoessl has received personal compensation for activities with Teva, Fujimoto, AbbVie, and UCB Pharma as a speaker/advisory board member/consultant.